Trial ID or NCT#

NCT02475681

Status

not recruiting iconNOT RECRUITING

Purpose

This study is evaluating the efficacy of obinutuzumab in combination with chlorambucil compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL).

Official Title

A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Caroline Berube
Caroline Berube
Hematologist
Clinical Associate Professor, Medicine - Hematology
Rondeep Brar
Rondeep Brar
Hematologist, Leukemia specialist, Medical oncologist
Clinical Associate Professor, Medicine - Hematology
David Iberri
David Iberri
Hematologist, Medical oncologist
Clinical Assistant Professor, Medicine - Hematology
Steven Coutre
Steven Coutre
Hematologist, Leukemia specialist

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061